- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03987178
Microbiologic Alterations of the Conjunctiva of Hot Tub-soaking Ophthalmologists (MACHO)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Keratitis is a rare destructive cause of blindness. It typically affects young and healthy individuals, is excruciatingly painful, and difficult to treat. With 60% of cases mis-diagnosed at presentation, acanthamoeba keratitis carries a far worse visual prognosis compared to other cornea infections. Exposure to hot tubs is a widely accepted risk factor. However, the mechanism of infection and prediction of who is at risk is unknown as the vast majority of hot tub users do not become infected.In vivo changes to ocular microbiology after hot tub exposure has never been described.
Changes to ocular microbiology after exposure to hot tubs have not been described. The purpose of this study is to investigate whether there are significant alterations in the microbiology of the conjunctiva after hot tub exposure that may contribute to these changes.
This study will recruit at least 34 subjects, who will be randomized to head submersion versus no head submersion, using at least three different hot tubs. A conjunctival swab, a minimal-risk test performed routinely in the eye clinic, will be performed before and after 15 minutes of hot tub exposure on one eye (randomized) per subject. The swabs will be plated on blood agar (bacterial cultures) and non-nutrient agar (acanthamoeba cultures).
In this prospective study, healthy subjects will be recruited. The study will be Health Insurance Portability and Accountability Act compliant and approved by the Institutional Review Board. All subjects will review and sign an informed consent form.
Each patient will have the conjunctiva of one eye (randomized) cultured. This practically no-risk technique entails touching a polyester-tip swab to the lining of the lower eyelid. Each subject will be randomized to head submersion or no head submersion; this exposure will be masked by the study coordinator. After 15 minutes of hot tub exposure, the subject will have the same eye swabbed for cultures.
Each sample (pre- and post-hot tub) will be randomly assigned a study number. One study coordinator will record and mask data. Water from each tub will be cultured.
The culture plates will be sent to our microbiology facility at UCSF and identification of organisms on the blood agar plates will be performed on our MALDI (mass spectrometry to identify bacteria and fungi). Non-nutrient agar plates will be plated with E. coli overlay and incubated for up to 7 days. The plates will be randomized and the microbiologists will be masked to exposures.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94122
- UCSF
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- greater of 18 years of age
- a willing participant
- healthy
Exclusion criteria:
- pregnancy
- high or low blood pressure
- active diarrhea
- lymphedema
- heart disease
- seizure disorder.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Head Dunk
Subjects who are assigned to be in this arm are asked to sit in a hot tub for 15 minutes and instructed to submerge his or her head in the hot tub at least once and at least up to the eyebrows during his or her time in the hot tub.
|
If randomized to "Dunk," the subject is asked to submerge his or her head in the hot tub at least up to brow level.
Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
|
Placebo Comparator: No Head Dunk
Subjects assigned to this arm are asked to sit in a hot tub for 15 minutes but to keep his or her chin above water during the entire time.
|
Subjects will be asked to sit in a hot tub for 15 minutes (with an individual timer).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantity of organisms
Time Frame: 1 year
|
Genus-species will be identified for each sample, and quantified with an ordinal scale (0-4). The total of this score will be the quantity for that person-time. The primary analyses will be a Wilcoxon Rank Sum test (Mann-Whitney) between the two arms at the follow-up time point (randomized comparison of dunk vs no-dunk), and a Wilcoxon Signed Rank test between pre-hot-tub and post-hot-tub (longitudinal comparison of all cases). We estimate that a total of 20 subjects will provide 80% power to detect a 1.25 SD difference in the total quantity score between randomization arms at the post (f/u) time point. We estimate 80% power to detect a .9 SD difference between pre (baseline) and post (f/u) time points in a paired longitudinal analysis. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Richness (number of species per sample) of organisms found in the conjunctiva with hot tub use (post-test comparison)
Time Frame: 1 year
|
The investigators will assess whether organism diversity (richness) changes between arms (post-test comparison) using Simpson's Diversity, expressed in units of effective number (see Jost).
We will also assess using Shannon's Diversity.
|
1 year
|
Richness (number of species per sample) of organisms found in the conjunctiva with hot tub use (pre versus post)
Time Frame: 1 year
|
The investigators will assess whether organism diversity (richness) changes longitudinally (pre vs post-test comparison).
|
1 year
|
Difference in organism profile with hot tub use (pre versus post)
Time Frame: 1 year
|
The investigators will determine whether the organism profile differs longitudinally (pre vs post-test comparison) using L-2 norm (Euclidean distance) and PERMANOVA.
We will also assess using L-1 norm (Manhattan distance)
|
1 year
|
Difference in organism profile with hot tub use (between arms)
Time Frame: 1 year
|
The investigators will determine whether the organism profile differs between arms (post-test comparison) using L-2 norm (Euclidean distance) and PERMANOVA.
We will also assess using L-1 norm (Manhattan distance)
|
1 year
|
Quantity comparing pre-hot tub and post-hot tub swabs
Time Frame: 1 year
|
We will compare quantity of organisms (amount and type) before and after hot tub use in both arms.
We will used a paired t-test for analysis.
|
1 year
|
Specific organisms found in the conjunctiva with hot tub use
Time Frame: 1 year
|
The investigators will compare specific organisms (Staphylococcus epidermidis, Corynebacterium species) between arms (post-test only) and longitudinally between time points (pre vs post-test) with Bonferroni correction
|
1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gerami D Seitzman, MD, UCSF/Proctor Foundation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-26141
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Conjunctivitis, Bacterial
-
Laboratoires TheaCompletedPurulent Bacterial ConjunctivitisFrance
-
IVIEW Therapeutics Inc.CompletedAcute Bacterial ConjunctivitisChina
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Bausch & Lomb IncorporatedCompletedAcute Bacterial Conjunctivitis
-
Azidus BrasilUnknownAcute Bacterial ConjunctivitisBrazil
-
ShireCompletedBacterial ConjunctivitisUnited States, Australia, Austria, Israel, Poland, Hungary, South Africa, Canada, Estonia, France, Italy, Spain, Puerto Rico
-
AllerganCompletedBacterial ConjunctivitisUnited States, India
-
Beijing Tongren HospitalZhuhai Essex Bio-Pharmaceutical Company Limited; Panacea TechnologiesUnknownBacterial ConjunctivitisChina
-
Merck Sharp & Dohme LLCCompletedBacterial ConjunctivitisUnited States
-
Alcon ResearchWithdrawn